Metraipolis › archive › dc_244bfb45d643

Adjuvant therapy for renal cell carcinoma: lessons from past failures and new opportunities in the era of immune checkpoint inhibition — Europe PMC PMID:42125664

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42125664
DOI: 10.3389/fimmu.2026.1816253
License (as archived): solo-consultazione
Archived: 2026-11-03T04:41:53.513Z
SHA-256 of the archived text: cee41d4f0c15863a496df18546de33c9ff6aa680b4a5171e553b7ca2ff47cfd5
Stable URL of this page: https://metraipolis.com/documento/dc_244bfb45d643

How to cite

Adjuvant therapy for renal cell carcinoma: lessons from past failures and new opportunities in the era of immune checkpoint inhibition — Europe PMC PMID:42125664 — Europe PMC (en), https://europepmc.org/article/MED/42125664 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_244bfb45d643 (Metraipolis archive dc_244bfb45d643, sha256 cee41d4f0c15863a496df18546de33c9ff6aa680b4a5171e553b7ca2ff47cfd5)

BibTeX

@misc{dc244bfb45d643,
  title = {Adjuvant therapy for renal cell carcinoma: lessons from past failures and new opportunities in the era of immune checkpoint inhibition — Europe PMC PMID:42125664},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42125664},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_244bfb45d643; sha256 cee41d4f0c15863a496df18546de33c9ff6aa680b4a5171e553b7ca2ff47cfd5},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42125664. Agents can read the archived copy with the MCP tool read_document.